TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer

Utpal K. Mukhopadhyay,Chetan Oturkar,Christina Adams,Nadi Wickramasekera,Sanjay Bansal,Rajesh Medisetty,Austin Miller,Wendy M. Swetzig,Laxmi Silwal-Pandit,Anne Lise Børresen-Dale,Chad J. Creighton,Jun Hyoung Park,Santhi D. Konduri,Alka Mukhopadhyay,Alexander Caradori,Angela Omilian,Wiam Bshara,Benny Abraham Kaipparettu,Gokul M. Das

TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer

2019

Utpal K. Mukhopadhyay
Chetan Oturkar
Christina Adams
Nadi Wickramasekera
Sanjay Bansal
Rajesh Medisetty
Austin Miller
Wendy M. Swetzig
Laxmi Silwal-Pandit
Anne Lise Børresen-Dale
Chad J. Creighton
Jun Hyoung Park
Santhi D. Konduri
Alka Mukhopadhyay
Alexander Caradori
Angela Omilian
Wiam Bshara
Benny Abraham Kaipparettu
Gokul M. Das

Background Anti-tumorigenic vs pro-tumorigenic roles of estrogen receptor-beta (ESR2) in breast cancer remain unsettled. We investigated the potential of TP53 status to be a determinant of the bi-faceted role of ESR2 and associated therapeutic implications for triple negative breast cancer (TNBC).

Keywords:

Breast cancer
Immunology
Cancer research
Biology
Estrogen receptor beta
Estrogen
Hazard ratio
Tamoxifen
Oncology
Internal medicine
Triple-negative breast cancer
Proportional hazards model
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations